Valuation dashboard for Perspective Therapeutics, Inc. (CATX) with P/E N/A, P/B 0.59, EV/EBITDA -2.37 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Analysis Summary
Trailing-twelve-month margins: gross margin -419.4%, operating margin -342.2%, net margin -318.1%.
At the current price of $2.88, CATX has negative trailing earnings (P/E not meaningful) and an ROE of -41.56%. Market capitalisation stands at $328M.
Balance sheet quality for CATX: current ratio of 5.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -2.37 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.14 |
| vs Current Price | -95.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | $328M | 0.59 | -41.6% | |
| ABT | Abbott Laboratories | $176.8B | 32.44 | 3.44 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.2B | |||
| MDT | Medtronic plc | $118.8B | 23.02 | 2.40 | 10.6% |
| SYK | Stryker Corporation | $107.4B | 29.46 | 4.58 | 16.4% |
| 0R2S.L | Stryker Corporation | $105.5B | 28.60 | 4.45 | 16.4% |
| BSX | Boston Scientific Corporation | $64.7B | 17.59 | 2.59 | 14.9% |
| 0HOY.L | Boston Scientific Corporation | $64.6B | 47.45 | 5.68 | 11.9% |
Price
| Price | $2.88 |
| Market Cap | $328M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | -41.56% |
| Return on Invested Capital | -34.94% |
| Return on Assets | -29.70% |
| Gross Margin | -419.40% |
| Operating Margin | -34216.39% |
| Net Margin | -31812.57% |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks